5%+ stake

Outlook Therapeutics (OTLK): Empery Asset Management, LP now owns 8.7% of OTLK as a passive investor 8.7%

Empery Asset Management, LP now owns 8.7% of OTLK as a passive investor.

8.7%
Stake
21.2M
Shares owned
Stake as of
Sep 30, 2026
Filed
Oct 13, 2026

Context

Written by software from the filings listed below · Oct 13, 2026

  • What was filed. Empery Asset Management, LP filed a SCHEDULE 13G on Oct 13, 2026, reporting 21,247,856 shares, 8.73% of the class of Outlook Therapeutics (OTLK). SEC Schedule 13G

2 more points, with the facts they come from, are in OQRO Pro.

Sign up free

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 12, 2026Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  2. Aug 12, 2026Insider · 11 days before an 8-KDirector purchased ~$2.5M of OTLK shares in the open market
  3. Aug 14, 2026Company filing · Form 8-K · ResultsReported its results
  4. Aug 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 23, 2026, Outlook Therapeutics, Inc. (the “Company”) and Lawrence A. Kenyon, the Company’s Chief Financial Officer, Treasurer and Corporate Secretary and a member of the Company’s Board of Directors (the “Board”), mutually agreed that Mr. Kenyon would cease serving in the roles of Chief Financial Officer, Treasurer, Corporate Secretary, principal financial officer and principal accounting officer,…”
  5. Sep 25, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On September 25, 2026, Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Staff (the “Nasdaq Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued…”

What came next

  1. Oct 13, 20265% stakeEmpery Asset Management, LP reported a passive stake (13G) of 8.7%
  2. Nov 16, 20265% stakeCVI Investments, Inc. reported a passive stake (13G) of 7.9%
View the official recordSEC Schedule 13G

How to read SEC Schedule 13G

A Schedule 13D and a Schedule 13G both disclose beneficial ownership of more than 5% of a US company's voting shares. A 13D is the long form, filed by holders who may seek to influence or control the company, and it must state what they intend to do. A 13G is the short form, open only to passive holders and to certain institutions holding in the ordinary course of business, and it asks no question about intent.

Full guide: Schedule 13D vs Schedule 13G: what is the difference?

What else is on file for Outlook Therapeutics

For Outlook Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its OTLK page.

How this filing works

Explore the data

Common questions

What does this filing report about Outlook Therapeutics (OTLK) stock?

Empery Asset Management, LP now owns 8.7% of OTLK as a passive investor. Of the company, Schedule 13G (passive).

When did it happen, and when was it made public?

Stake as of: Sep 30, 2026. Filed: Oct 13, 2026.

Is this a trade made on a known date?

No. A holdings report is a picture of the portfolio on the last day of the quarter. It shows what was held on that day, not the day or the price at which anything was bought or sold.

Where does this information come from?

From the SEC Schedule 13G, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.

What else has been disclosed about Outlook Therapeutics recently?

For Outlook Therapeutics, OQRO holds 1 fund holdings report (13F) dated in the last 90 days. They are listed on the OTLK page.

Does this mean OTLK stock is a buy or a sell?

No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.

Is OQRO free?

Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.

Other disclosures at Outlook Therapeutics

Everything OQRO holds on this company is on its OTLK page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data